focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics Group

6 Feb 2013 11:18

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group

PR Newswire

London, February 6

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A

PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Identity of the person whose positions/ Aberforth Partners LLP, on

dealings are being disclosed: behalf of discretionary clients. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to Ark Therapeutics Group plc whose relevant securities this form relates: Use a separate form for each offeror/offeree (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 05 February 2013 (f) Has the discloser previously disclosed, or Y/N NO are they today disclosing, under the Code in respect of any other party to this offer? If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror orofferee to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary Shares Interests Short positions Number % Number % (1) Relevant securities owned 28,860,092 13.79 0 0.0 and/or controlled: (2) Derivatives (other than options): (3) Options and agreements to purchase/sell: TOTAL: 28,860,092 13.79 0 0.0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchaseor sell relevant securities, should be given on a Supplemental Form 8 (OpenPositions).

(b) Rights to subscribe for new securities (including directors' and otherexecutive options)

Class of relevant security in N/A relation to which subscription right exists: Details, including nature of the N/A rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than oneclass of relevant securities of the offeror or offeree named in 1(c), copytable 2(a) or (b) (as appropriate) for each additional class of relevantsecurity.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit security securities Ordinary Shares Sale 2,915,000 1.009p

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per relevant description reference unit security e.g. opening/closing a securities e.g. CFD long/short position, increasing/reducing a long/short position N/A

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option relevant description purchasing, securities price

date money security e.g. call selling, to which per unit e.g.

paid/

option varying option American, received etc. relates European per unit etc. N/A (ii) Exercising Class of relevant Product Number of Exercise price per security description securities unit e.g. call option N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit security (if applicable) e.g. subscription, conversion N/A

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities ofthe offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (asappropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or

understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person

making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none" None

(b) Agreements, arrangements or understandings relating to options orderivatives

Details of any agreement, arrangement or understanding, formal or informal,

between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 06 February 2013 Contact name: David Holland, for Aberforth Partners LLP Telephone number: 0131 220 0733

Public disclosures under Rule 8 of the Code must be made to a RegulatoryInformation Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk . The Panel's Market Surveillance Unit isavailable for consultation in relation to the Code's dealing disclosurerequirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .
Date   Source Headline
22nd Mar 20185:39 pmRNSNotification of major holdings
12th Mar 201811:38 amRNSHolding(s) in Company
19th Feb 20182:54 pmRNSHolding(s) in Company
5th Feb 201811:25 amRNSDirectorate Change
1st Feb 20185:26 pmRNSResult of AGM
1st Feb 20187:00 amRNSAGM Update
26th Jan 201810:36 amRNSBlock listing Interim Review
20th Dec 201712:08 pmRNSHolding(s) in Company
15th Dec 20174:53 pmRNSNotice of AGM
12th Dec 20177:00 amRNSNew Partnership with MWI Animal Health
28th Nov 20177:00 amRNSFinal Results
2nd Nov 201710:44 amRNSHolding(s) in Company
18th Oct 20177:00 amRNSFurther re Trading update
17th Oct 20177:00 amRNSDirectorate Change
27th Sep 20175:32 pmRNSChange of Auditor
27th Sep 20174:43 pmRNSDirector/PDMR Shareholding
22nd Sep 20171:36 pmRNSHolding(s) in Company
22nd Sep 20177:00 amRNSTrading Update
21st Sep 20174:07 pmRNSHolding(s) in Company
15th Sep 20173:26 pmRNSHolding(s) in Company
14th Sep 20175:00 pmRNSHolding(s) in Company
26th Jul 20175:40 pmRNSHolding(s) in Company
20th Jun 20177:00 amRNSBlock Listing Six Monthly Return
7th Jun 20173:15 pmRNSHolding(s) in Company
7th Jun 20173:08 pmRNSHolding(s) in Company
23rd May 20177:00 amRNSInterim Results for six months ended 31 March 2017
5th May 20172:59 pmRNSHolding(s) in Company
2nd May 20177:00 amRNSTrading update
2nd May 20177:00 amRNSSuccessful completion of business sale
31st Mar 20179:34 amRNSHolding(s) in Company
31st Mar 20179:34 amRNSHolding(s) in Company
31st Mar 20179:27 amRNSTotal Voting Rights
28th Mar 201712:27 pmRNSBlock Listing Application
14th Mar 201711:55 amRNSHolding(s) in Company
14th Mar 201711:52 amRNSHolding(s) in Company
14th Mar 201711:04 amRNSHolding(s) in Company
13th Mar 20173:47 pmRNSHolding(s) in Company
10th Mar 20174:14 pmRNSDirectors' Dealings
7th Mar 20175:27 pmRNSDirector's Dealings
3rd Mar 20173:41 pmRNSResult of AGM
16th Feb 201711:31 amRNSAppointment of Broker
16th Feb 20177:00 amRNSFURTHER AGREEMENT IN US FOR PREMIER PET CARE PLAN
2nd Feb 20173:55 pmRNSHolding(s) in Company
31st Jan 201712:11 pmRNSPremier Pet Care Plan Growth and Loan Note Update
20th Dec 201610:59 amRNSBlock listing Interim Review
19th Dec 201611:37 amRNSReceipt of £1m deferred consideration
12th Dec 201611:37 amRNSHolding(s) in Company
29th Nov 20167:00 amRNSFinal Results
9th Nov 201610:30 amRNSHolding(s) in Company
12th Oct 20167:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.